NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
Status:
Terminated
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and
750mg/m2) in patients with ovarian cancer. The primary objective was to determine the
anti-tumor activity of NUC-1031 at the selected dose level (500 mg/m2 or 750 mg/m2).